PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SCB 901 PCT	FOR FURTHER ACTION		See Form PCT/IPEA/416								
International application No. PCT/EP2005/000987	International filing date 01.02.2005	(day/month/year)	Priority date (day/month/year) 03.02.2004								
International Patent Classification (IPC) or national classification and IPC INV. C07C323/00											
Applicant INDENA S.P.A.											
1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.											
2. This REPORT consists of a total of											
3. This report is also accompanied b	y ANNEXES, comprisi	ng:									
a. 🖾 sent to the applicant and to	o the International Bure	eau) a total of 1 sheets	s, as follows:								
sheets of the descripti and/or sheets containi											
□ sheets which supersed beyond the disclosure Supplemental Box.	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the										
sequence listing and/or tab	b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).										
4. This report contains indications re	elating to the following i	tems:									
☐ Box No. I Basis of the rep	ort										
☐ Box No. II Priority											
☐ Box No. III Non-establishm	ent of opinion with rega	ard to novelty, inventive	step and industrial applicability								
applicability; cita	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement										
	Box No. VI Certain documents cited										
_	in the international app										
☐ Box No. VIII Certain observations on the international application											
Date of submission of the demand		Date of completion of th	nis report								
07.11.2005		26.04.2006									
Name and mailing address of the internation preliminary examining authority:		Authorized officer	Status Petentony								
European Patent Office - P.B. NL-2280 HV Rijswijk - Pays B Tel. +31 70 340 - 2040 Tx: 31 Fax: +31 70 340 - 3016	as	English, R Telephone No. +31 70 3	340-2860								

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2005/000987

	Box	k No. I Basis of the report					
1.	Witl	h regard to the language, this report is based on					
		the international application in the language in which it was filed					
		a translation of the international application into, which is the language of a translation furnished for the purposes of: international search (under Rules 12.3(a) and 23.1(b))					
		□ publication of the international application (under Rule 12.4(a)) □ international preliminary examination (under Rules 55.2(a) and/or 55.3(a))					
2.	With regard to the elements* of the international application, this report is based on (replacement sheets where the content of the sheet in the						
	Des	cription, Pages					
1-12		as originally filed					
	Clai	ms, Numbers					
	1-6	received on 07.11.2005 with letter of 07.11.2005					
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing					
3.		The amendments have resulted in the cancellation of:					
		☐ the description, pages☐ the claims, Nos.					
		☐ the drawings, sheets/figs					
		 □ the sequence listing (specify): □ any table(s) related to sequence listing (specify): 					
1.	□ had Sup	This report has been established as if (some of) the amendments annexed to this report and listed below not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the plemental Box (Rule 70.2(c)).					
		☐ the description, pages					
		☐ the claims, Nos.☐ the drawings, sheets/figs					
		☐ the sequence listing (specify): ☐ any table(s) related to sequence listing (specify):					
	*	If item 4 applies, some or all of these sheets may be marked "superseded."					

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1		Si	haf	a	m	ام	nt
	_	. 1				T	

Novelty (N)

Yes: Claims

1-6

No:

Claims

Inventive step (IS)

Yes: Claims

1-6

No: Claims

Industrial applicability (IA)

Yes: Claims

1-6

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet



INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

PCT/EP2005/000987

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following document:

D1: WO 01/68597 A (Indena) 20 September 2001

1. Subject-matter

The present application concerns compounds containing two N-deacetylthio-colchicine groups linked together via a cyclic linker group. These compounds have antitumour, antiarthritic, antiinflammatory and antiviral activity.

2. Novelty

Document D1 discloses (see examples) compounds containing two N-deacetylthio-colchicine groups linked together via linkers with the formulae $CO(CH_2)_{2-10}CO$ and $CONHCH_2CH_2CO$. Compounds of present claim 1 are not disclosed in D1 or anywhere else in the prior art. Consequently, the subject-matter of claims 1-6 appears to be new and to satisfy the requirements of Article 33(2) PCT.

3. Inventive step

The document D1 is regarded as being the closest prior art to the subject-matter of claims 1-6, and discloses compounds containing two N-deacetylthiocolchicine groups linked together via linkers which are not part of the scope of the present invention or are excluded from it and their use in the treatment of tumours and rheumatoid arthritis. These prior-art compounds differ from those of the present application in that the latter have a cyclic group as the linker between the two N-deacetylthio-colchicine groups in place of the acyclic alkylene group of the former.

A comparison of the pharmacological data provided by the applicant shows that the compounds of the present invention in which the linker contains a cyclic group (examples 1-4) show an improved activity (lower IC₅₀) against certain cancers (MCF7, A2780, Widr) compared to one compound of D1 in which the linker is acyclic. The problem to be solved by the present invention may therefore be regarded as the provision of improved compounds for antitumour, antiarthritic, antiinflammatory and antiviral use. The applicant solves this problem by means of the compounds of present claim 1 as demonstrated in the description (table 2).

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2005/000987

It would not be obvious to the person skilled in the art that replacement of the linker groups of D1 with those of the present application would lead to improved compounds for antitumour, antiarthritic, antiinflammatory and antiviral use. Consequently, the subject-matter of the present claims appears to involve an inventive step and to satisfy the requirements of Article 33(3) PCT.

10/588012 13 AP20 REC'OPCT/PTO 51 AUG 2006

CLAIMS

1. Compounds of formula I

in which:

5

- the linker is C₃-C₈ cycloalkyl, a phenylene or C₄-C₆ heterocyclic ring; and
- the G junctions are both -CO- or -CONH.
- 2. Compounds as claimed in claim 1 in which the *linker* is selected from 1,3-ciclohexylene and 1,4-cyclohexylene.
 - 3. Compounds as claimed in claim 1 or 2 in which the linker is selected from 1,2-, 1,3- or 1,4-phenylene.
- 4. Compounds as claimed in claim 1 in which the *linker* is selected from pyridyl, piperidinyl, piperazinyl linked to the G₁ and G₂ groups in the positions 3,5 or 2,5 or 2,6.
 - 5. The compounds of formula I for antitumour, antiarthritis, antiinflammatory and antiviral use.
- 6. Pharmaceutical compositions containing the compounds of formula I as active ingredients in admixture with suitable carriers and/or excipients.